ArticleInternational dental journal2026
Curcumin suppresses EMT to alleviate oral submucous fibrosis progression through XIST/miR-25-3p-mediated inactivation of the TGF-β1/Smads signalling pathway.
Article in International dental journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Curcumin and Its Derivatives as Anticancer Agents in Head and Neck Cancer: Molecular Mechanisms and Preclinical Evidence.International journal of molecular sciences · 2026Review
- Isoliquiritigenin represses the pro-fibrotic TGF-β/smad2 signaling and nuclear enriched abundant transcript 1 (NEAT1) in oral submucous fibrosis.Journal of dental sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOral submucous fibrosis (OSF) is a chronic oral disease with a tendency to carcinogenesis. At present, the treatment of OSF is limited and ineffective, and there is an urgent need to find new effective drugs and mechanisms of action.
methodsArecoline was used to induce human oral mucosal fibroblasts (HOFs) to establish OSF cell model. The effects of curcumin on the proliferation, migration and invasion of HOFs were detected by CCK-8 and Transwell. Western blot (WB) was used to detect the effect of curcumin on epithelial-mesenchymal transition (EMT) process and TGF-β1/Smads signalling pathway. The regulation of XIST and miR-25-3p expression by curcumin was detected by qRT-PCR, and the role of XIST/miR-25-3p axis in curcumin function was investigated by rescue assay to detect cell viability, EMT progression and TGF-β1/Smads signalling pathway.
resultsCurcumin significantly inhibited HOF cell viability (about 58%) and EMT process, down-regulate the expression of mesenchymal markers N-cadherin and Vimentin (over 40%), up-regulate the expression of epithelial marker E-cadherin (twice), and inhibit the activation of TGF-β1/Smads signalling pathway (about 50%). Curcumin regulated the expression levels of XIST (downregulated by approximately 58%) and miR-25-3p (increased by more than twice), and XIST regulated the expression of miR-25-3p through sponge adsorption. Further studies confirmed that curcumin regulated HOF cell activity, EMT process and TGF-β1/Smads signalling pathway through the XIST/miR-25-3p axis.
conclusionsCurcumin effectively inhibits EMT by inactivating the TGF-β1/Smads pathway through regulating XIST/miR-25-3p, and thereby alleviating the progression ofOSF. The study results further reveal the mechanisms underlying the function of curcumin, and may provide novel targets and ideas for OSF therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.